SynthesisTranslational stroke research2026
Brain-Derived Neurotrophic Factor Val66Met Polymorphism and Cognitive Outcome after Stroke: A Systematic Review.
Synthesis in Translational stroke research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Post-stroke cognitive impairment (PSCI) is a common and disabling consequence of stroke. Brain-derived neurotrophic factor (BDNF) plays important roles in neuroplasticity, and the BDNF Val66Met (rs6265) polymorphism may alter cognitive outcomes after stroke; however, evidence remains inconsistent. We searched PubMed, Scopus, and Web of Science. Observational studies involving adults with stroke that evaluated the association between BDNF Val66Met and post-stroke cognitive outcomes were included. Two reviewers independently screened studies; one reviewer extracted and another verified the data. Methodological quality was assessed using the Newcastle-Ottawa Scale. Findings were synthesized narratively because of substantial heterogeneity in study population, genotype classification, and cognitive measures. Seven studies involving 2,494 participants met the inclusion criteria. Five studies evaluated global cognitive outcomes. Four reported significant genotype-related associations or differences in global cognition, with three showing poorer cognitive outcomes among Met-allele carriers and one reporting the opposite direction. In the largest cohort, Met carriers had significantly lower 12-month telephone Montreal Cognitive Assessment scores after adjustment for covariates. Memory was the most consistently affected domain, with poorer performance among Met carriers. Evidence for language was inconsistent, while data on attention and executive function were limited. One cohort reported an opposite association, with Val-allele carriers demonstrating poorer global cognition and language performance. One study also identified poorer cognitive functional recovery among Met carriers. BDNF Val66Met may be associated with variability in post-stroke cognitive outcomes, particularly global cognition and memory. However, population-specific findings and methodological heterogeneity preclude definitive conclusions. Larger prospective multicenter studies using standardized cognitive assessments are warranted.
Indexed as
Identifiers
42828579What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.